U.S. Shingles Vaccine Market (2025 - 2033) Size, Share & Trends Analysis Report By Product (Shingrix, Zostavax, SkyZoster), By Vaccine Type (Recombinant Vaccine, Live Attenuated Vaccine), By End Use, And Segment Forecasts

Table of Contents

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation & Scope
                    1.2. Segment Definitions
                        1.2.1. Product
                        1.2.2. Vaccine type
                        1.2.3. End Use
                        1.2.4. Estimates and forecasts timeline
                    1.3. Research Methodology
                    1.4. Information Procurement
                        1.4.1. Purchased database
                        1.4.2. GVR’s internal database
                        1.4.3. Secondary sources
                        1.4.4. Primary research
                        1.4.5. Details of primary research
                            1.4.5.1. Data for primary interviews in U.S.
                    1.5. Information or Data Analysis
                        1.5.1. Data analysis models
                    1.6. Market Formulation & Validation
                    1.7. Model Details
                        1.7.1. Commodity flow analysis (Model 1)
                        1.7.2. Approach 1: Commodity flow approach
                        1.7.3. Volume price analysis (Model 2)
                        1.7.4. Approach 2: Volume price analysis
                    1.8. List of Secondary Sources
                    1.9. List of Primary Sources
                    1.10. Objectives
Chapter 2. Executive Summary
                    2.1. Market Outlook
                    2.2. Segment Outlook
                        2.2.1. Product outlook
                        2.2.2. Vaccine type outlook
                        2.2.3. End Use outlook
                    2.3. Competitive Insights
Chapter 3. U.S. Shingles Vaccine market Variables, Trends & Scope
                    3.1. Market Lineage Outlook
                        3.1.1. Parent market outlook
                        3.1.2. Related/ancillary market outlook
                    3.2. Market Dynamics
                        3.2.1. Market driver analysis
                            3.2.1.1. Aging Population & Rising Shingles Incidence
                            3.2.1.2. Government Programs & Outreach Initiatives
                        3.2.2. Market restraint analysis
                            3.2.2.1. High Vaccine Cost & Financial Barriers
                            3.2.2.2. Vaccine Hesitancy & Logistical Hurdles
                            3.3. U.S. shingles vaccine market Analysis Tools
                        3.3.1. Industry Analysis - Porter’s
                            3.3.1.1. Supplier power
                            3.3.1.2. Buyer power
                            3.3.1.3. Substitution threat
                            3.3.1.4. Threat of new entrant
                            3.3.1.5. Competitive rivalry
                        3.3.2. PESTEL Analysis
                            3.3.2.1. Political landscape
                            3.3.2.2. Technological landscape
                            3.3.2.3. Economic landscape
Chapter 4. U.S. Shingles Vaccine Market: Product Estimates & Trend Analysis
                    4.1. Product Market Share, 2024 & 2033
                    4.2. Segment Dashboard
                    4.3. U.S. Shingles Vaccine Market by Product Outlook
                    4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
                        4.4.1. Shingrix
                            4.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
                        4.4.2. Zostavax
                            4.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
                        4.4.3. SKYZoster
                            4.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 5. U.S. Shingles Vaccine Market: Vaccine type Estimates & Trend Analysis
                    5.1. Vaccine type Market Share, 2024 & 2033
                    5.2. Segment Dashboard
                    5.3. U.S. Shingles Vaccine Market by Vaccine type Outlook
                    5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
                        5.4.1. Recombinant Vaccine
                            5.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
                        5.4.2. Live Attenuated Vaccine
                            5.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 6. U.S. Shingles Vaccine Market: End Use Estimates & Trend Analysis
                    6.1. End Use Market Share, 2024 & 2033
                    6.2. Segment Dashboard
                    6.3. U.S. Shingles Vaccine Market by End Use Outlook
                    6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
                        6.4.1. Private Healthcare Settings
                            6.4.1.1. Market estimates and forecasts 2021 to 2033 (USD million)
                        6.4.2. Government Healthcare Settings
                            6.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 7. Competitive Landscape
                    7.1. Recent Developments & Impact Analysis, By Key Market Participants
                    7.2. Company/Competition Categorization
                    7.3. Vendor Landscape
                        7.3.1. List of key distributors and channel partners
                        7.3.2. Key customers
                        7.3.3. Key company market share analysis, 2024
                        7.3.4. GlaxoSmithKline plc.
                            7.3.4.1. Company overview
                            7.3.4.2. Financial performance
                            7.3.4.3. Product benchmarking
                            7.3.4.4. Strategic initiatives
                        7.3.5. Pfizer Inc.
                            7.3.5.1. Company overview
                            7.3.5.2. Financial performance
                            7.3.5.3. Product benchmarking
                            7.3.5.4. Strategic initiatives
                        7.3.6. Merck & Co., Inc.
                            7.3.6.1. Company overview
                            7.3.6.2. Financial performance
                            7.3.6.3. Product benchmarking
                            7.3.6.4. Strategic initiatives
                        7.3.7. CanSinoBIO
                            7.3.7.1. Company overview
                            7.3.7.2. Financial performance
                            7.3.7.3. Product benchmarking
                            7.3.7.4. Strategic initiatives
                        7.3.8. Vaccitech
                            7.3.8.1. Company overview
                            7.3.8.2. Financial performance
                            7.3.8.3. Product benchmarking
                            7.3.8.4. Strategic initiatives
                        7.3.9. Green Cross Corp
                            7.3.9.1. Company overview
                            7.3.9.2. Financial performance
                            7.3.9.3. Product benchmarking
                            7.3.9.4. Strategic initiatives
                        7.3.10. Geneone Life Science
                            7.3.10.1. Company overview
                            7.3.10.2. Financial performance
                            7.3.10.3. Product benchmarking
                            7.3.10.4. Strategic initiatives
                        7.3.11. SK Bioscience
                            7.3.11.1. Company overview
                            7.3.11.2. Financial performance
                            7.3.11.3. Product benchmarking
                            7.3.11.4. Strategic initiatives

List of Tables

Table 1 List of abbreviation
Table 2 U.S. Shingles Vaccine Market, by Product, 2021 - 2033 (USD Million)
Table 3 U.S. Shingles Vaccine Market, by Vaccine type, 2021 - 2033 (USD Million)
Table 4 U.S. Shingles Vaccine Market, by End Use, 2021 - 2033 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in U.S.
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 U.S. Shingles Vaccine Market: market outlook
Fig. 10 U.S. Shingles Vaccine competitive insights
Fig. 11 Parent market outlook
Fig. 12 Related/ancillary market outlook
Fig. 13 Penetration and growth prospect mapping
Fig. 14 Industry value chain analysis
Fig. 15 U.S. Shingles Vaccine Market driver impact
Fig. 16 U.S. Shingles Vaccine Market restraint impact
Fig. 17 U.S. Shingles Vaccine Market strategic initiatives analysis
Fig. 18 U.S. Shingles Vaccine Market: Product movement analysis
Fig. 19 U.S. Shingles Vaccine Market: Product outlook and key takeaways
Fig. 20 Shingrix market estimates and forecast, 2021 - 2033
Fig. 21 Zostavax market estimates and forecast, 2021 - 2033
Fig. 22 SKYZoster market estimates and forecast, 2021 - 2033
Fig. 23 U.S. Shingles Vaccine Market: Vaccine type movement Analysis
Fig. 24 U.S. Shingles Vaccine Market: Vaccine type outlook and key takeaways
Fig. 25 Recombinant Vaccine market estimates and forecasts, 2021 - 2033
Fig. 26 Live Attenuated Vaccine market estimates and forecasts,2021 - 2033
Fig. 27 U.S. Shingles Vaccine Market: End Use movement analysis
Fig. 28 U.S. Shingles Vaccine Market: End Use outlook and key takeaways
Fig. 29 Private Healthcare Settings market estimates and forecasts, 2021 - 2033
Fig. 30 Government Healthcare Settings market estimates and forecasts,2021 - 2033
Fig. 31 U.S. Shingles Vaccine Market share and leading players
Fig. 32 U.S. market share and leading players
Fig. 33 U.S. SWOT
Fig. 34 U.S. market estimates and forecasts, 2021 - 2033
Fig. 35 Market share of key market players- U.S. Shingles Vaccine Market